Precision medicine is redefining what’s clinically possible, but not what’s commercially guaranteed. In the US, biomarker-driven and companion diagnostic–led therapies face persistent access barriers, including fragmented coverage, pricing pressures and evidence limitations driven by small, targeted populations and reliance on surrogate endpoints. As a result, clinical efficacy alone is no longer sufficient to secure payer-recognized value or reimbursement.
This webinar brings together cross-functional experts to explore how developers can close this gap: designing data and evidence strategies that translate precision innovation into real-world, decision-ready value across payers, providers and patients.
Attendees will learn how to:
- Navigate US access barriers and evolving payer expectations for precision therapies
- Understand and address evidence gaps in small, biomarker-defined populations
- Leverage real-world data and external comparators to validate endpoints and demonstrate value
- Integrate patient-centered evidence to strengthen differentiation and decision relevance
- Build multi-stakeholder evidence strategies, with tailored approaches for rare oncology and neurology
By the end of this session, attendees will have a clear, practical framework for transforming precision therapies from promising science into payer-relevant, evidence-backed value propositions, enabling more predictable access, stronger reimbursement outcomes and sustainable commercial success.
Register for this webinar to learn how precision therapies can move from promising science to payer-relevant, evidence-backed value propositions that support access and reimbursement.
Speakers
Adam Petrich, MD, Vice President, Oncology, Medical Science and Strategy, Thermo Fisher Scientific
Dr. Petrich brings more than 20 years of experience in oncology clinical development across pharmaceutical and biotech settings. He leads strategic clinical trial design and execution with a focus on biospecimen-driven precision oncology, including the integration of biomarker strategies and AI-enabled approaches to improve patient selection and clinical outcomes. Dr. Petrich has guided multiple therapies from early development through regulatory approval and launch and is board-certified in oncology, hematology and internal medicine.
Message Presenter
Priya Jain, MS, MBA, Executive Director, PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific
Priya brings more than 17 years of global biotech and pharmaceutical experience with deep expertise in market access and product commercialization. She partners with clients to develop integrated strategies spanning pricing, payer evidence, patient access and reimbursement, helping ensure therapies demonstrate clear value across stakeholders and achieve commercial success. Priya has extensive experience across therapeutic areas, including oncology, immunology and rare diseases, and is known for aligning evidence generation and market access strategy to support optimal patient access.
Message Presenter
John Hamlet, Executive Director, Neuroscience Pillar Head, Thermo Fisher Scientific
John brings more than 30 years of experience in the clinical research and pharmaceutical industry. He leads global neuroscience drug development programs across complex indications, overseeing study execution, operational strategy and data integrity to ensure consistent, high-quality delivery. John also champions advanced scientific surveillance approaches to enhance signal detection, mitigate placebo response and strengthen trial quality while driving operational excellence in neurologic drug development.
Message Presenter
Amanda Pulfer, BA, Executive Director, Integrated Solutions, RWE, PPD Evidera Real-World Data & Scientific Solutions, Thermo Fisher Scientific
Amanda leads the development of integrated real-world data (RWD) and real-world evidence (RWE) solutions, designing innovative studies that balance client objectives with scientific rigor. With more than 25 years of experience, she partners with biopharma organizations to generate impactful evidence across the product lifecycle, supporting decision-making from development through commercialization. Amanda brings broad therapeutic expertise, including oncology, rare diseases and immunology, and a strong focus on translating complex data into actionable insights.
Message Presenter
Elizabeth Dansie Bacci, PhD, Senior Research Scientist, PPD Evidera Patient-Centered Research, Thermo Fisher Scientific
Dr. Dansie Bacci brings more than 15 years of experience in outcomes research across a wide range of therapeutic areas, including rare disease, neurology and chronic conditions. She specializes in the development, validation and implementation of patient-reported outcome measures to support clinical trials and real-world studies, with a focus on ensuring endpoints are meaningful to patients, clinicians and payers.
Dr. Dansie Bacci also brings deep expertise in study design, psychometric evaluation and advanced analytics, helping translate patient-centered data into evidence that strengthens clinical and value-based decision-making.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Clinical Development and Translational Leaders designing biomarker-driven precision studies (oncology, neurology, rare disease and cell and gene therapy)
- Market Access, HEOR and Evidence Strategy Leaders responsible for payer value and reimbursement
- Regulatory and Medical Affairs Leaders shaping evidence and endpoint strategy
- Real-World Evidence and Data Science teams supporting external comparators and post-approval value
- Commercial and Portfolio Strategy Leaders aligning clinical differentiation with access and pricing
- Program leadership (global program heads, cross-functional leads) driving integrated development-to-commercial plans
What You Will Learn
Attendees will learn how to:
- Navigate US payer expectations for biomarker-driven therapies
- Address evidence gaps in small, targeted populations and validate endpoints
- Use real-world data and external comparators to demonstrate value
- Build integrated, cross-functional evidence strategies that support reimbursement and access
Xtalks Partner
PPD (Thermo Fisher Scientific)
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, their capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, they serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, they apply cutting edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account